Why the study?
Many pharmacologic regimens derive from trials in general populations with limited data on the critically ill, who frequently require off-label medications and individualized management plans.
Developing precision-based pharmacotherapy plans in critically ill patients requires a multidisciplinary approach, continuous assessment, and integration of complex clinical factors.
Answers are grounded in this paper and cite their sources.
Off-label use remains common in critically ill patients; leaves open need for individualized RCT evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
William E. Dager (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: